Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice

Get up to date on the latest advances on incorporating CD38 antibodies into treatment regimens for multiple myeloma to improve outcomes and consider strategies for how to provide more equitable access to high-quality multiple myeloma care with downloadable slides and an on-demand webcast from a workshop series.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Sanofi.

Sanofi